Wed, Jul 23, 2014, 5:32 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Shire plc Message Board

rosengroup2001 3 posts  |  Last Activity: Jul 6, 2014 3:06 PM Member since: May 19, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Just for thought

    by rosengroup2001 Jul 6, 2014 1:33 PM
    rosengroup2001 rosengroup2001 Jul 6, 2014 3:06 PM Flag

    I disagree. It's logical that "enrollments" would cease while current data is being analyzed.What's the point of enrolling more people if (1) the data, as presented satisfies the DSMB's requirements OR (2) the data, as presented, shows that this drug will never see the light of day? No new enrollments during this analysis process is just a by-product of the analysis. Why spend more money proving (or disproving) what the data is already showing? I still believe that the drug is viable because there hasn't been any adverse allergic reaction to date. I don't think the DSMB analysis will prove otherwise.

  • rosengroup2001 by rosengroup2001 Jul 6, 2014 1:33 PM Flag

    Rgdo conference call reiterated that they are not privy to data. Consider this possibility: is data so strong at this point that there is no reason to enroll more patients? Is it possible that data to date shows no adverse allergic reaction so additional review is not necessary? This is a large sample group of more than 3,000 patients so could it be possible that investigators have all they need at this point in time. Not sure where stock goes from here but not sure this is bad ness at all . Thoughts?

  • rosengroup2001 rosengroup2001 Jun 23, 2014 9:51 AM Flag

    Check out officers' holdings - other than CEO, VERY light.

SHPG
255.03+1.07(+0.42%)Jul 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.